Advertisement
Organisation › Details
Affimed N.V. (Nasdaq: AFMD)
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. *
Start | 2014-09-17 existent | |
Group | Affimed (Group) | |
Predecessor | Affimed Therapeutics AG | |
Industry | MAb, human, fully | |
Industry 2 | TandAb bispecific antibody | |
Person | Fischer, Wolfgang (Affimed 201709– COO before Sandoz Biopharmaceuticals + Novartis) | |
Person 2 | Harstrick, Andreas (Affimed 202204 CMO) | |
Region | Mannheim | |
Country | Germany | |
Street | 2 Gottlieb-Daimler-Str. | |
City | 68165 Mannheim | |
Tel | +49-621-56003-0 | |
Address record changed: 2024-04-05 | ||
Basic data | Employees | D: 101 to 500 (2021-12-31) |
Currency | EUR | |
Annual sales | 41,353,000 (revenue, consolidated (2022) 2022-12-31) | |
Profit | -86,004,000 (2022-12-31) | |
Cash | 190,286,000 (2022-12-31) | |
* Document for »About Section«: Affimed N.V.. (3/6/24). "Press Release: Affimed Announces 1-for-10 Reverse Stock Split". Mannheim. | ||
Record changed: 2024-04-07 |
Advertisement
More documents for Affimed (Group)
- [1] Affimed N.V.. (3/6/24). "Press Release: Affimed Announces 1-for-10 Reverse Stock Split". Mannheim....
- [2] Affimed N.V.. (1/3/24). "Press Release: Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck". Mannheim....
- [3] Affimed N.V.. (11/3/22). "Press Release: Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101". Heidelberg & San Diego, CA....
- [4] Affimed N.V.. (11/1/22). "Press Release: Affimed to Present at the 2022 Jefferies London Healthcare Conference". Heidelberg....
- [5] Affimed N.V.. (9/1/22). "Press Release: Affimed to Present at Upcoming Investor Conferences". Heidelberg....
- [6] Affimed N.V.. (4/13/22). "Press Release: Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares". Heidelberg....
- [7] Affimed N.V.. (4/12/22). "Press Release: Affimed Announces Proposed Public Offering of Common Shares". Heidelberg....
- [8] Affimed N.V.. (4/10/22). "Press Release: Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting". Heidelberg....
- [9] Affimed N.V.. (4/8/22). "Press Release: Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors". Heidelberg....
- [10] Affimed N.V.. (3/31/22). "Press Release: Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress". Heidelberg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top